Claims Scope:

Patent issued February 2, 2023. 

Sequence agnostic claims – Comp & Methods 

 Composition claims targeting FDPS and either (i) activating a GD T cell or (ii) having an envelope protein capable of infecting a cancer cell; (narrower than prior issued Israeli patent).  Method claims for treating cancer. Addresses single reference arising in foreign prosecution. Also require a helper and envelope.  Combination claims also include amino bisphosphonates.